Test | Memory component | Validation |
---|---|---|
Memory Capacity Test [13] | Verbal associative binding | 34 HC, decrements in second-list learning associated with amyloid burden |
Cross-model associative binding | 45 HC, decrements in face name versus face occupation associated with amyloid burden | |
210 HC, good test–retest and discriminate validity for name, occupation and summary scores, useful across all educational strata | ||
129 HC, FNAME performance summary scores were associated with reduced hippocampal volume and APOE4 carrier status | ||
Short-Term Memory Binding test [41] | Visual recognition, change detection, feature binding | 30 asymptomatic carriers with E280A mutation showed impairment in visual short-term memory binding, suggesting short-term memory binding may be a preclinical marker for familial AD |
Visual recognition, pattern separation | 31 HC, impairments in pattern separation were noted in those with weaker RAVLT Delayed Recall Scores. Recognition Memory was normal. In 23 aMCI individuals, pattern separation deficits improved in those exposed to drug treatment during a clinical trial | |
Visual recognition, pattern separation, spatial discrimination | 37 HC, Spatial Pattern Separation performance was associated with reduced bilateral hippocampal volume and with the CSF Aβ42/pTau181 ratio. Paragraph recall was not sensitive to these biomarker correlates | |
Spatial discrimination | 37 HC, reduced transfer performance was associated with mild-to-moderate hippocampal atrophy in CN and associated with clinical impairment 2 years later. Performance also correlated with CSF Aβ42 and the Aβ42/pTau181 ratio | |
Spatial discrimination | 39 E280A mutation carriers showed dual tasking impairments despite normal performances on other standard neuropsychological tests of cognition and memory. Dual tasking performance discriminates asymptomatic carriers with familial AD from healthy controls |